
Opinion|Videos|April 11, 2025
Recurrence Rates in Uncomplicated UTIs
Panelists discuss how significant gaps in current uncomplicated urinary tract infection (UTI) therapies include insufficient nonantibiotic preventive strategies, limited options for multidrug-resistant pathogens, inadequate personalized treatment approaches, minimal focus on biofilm disruption, lack of rapid point-of-care diagnostics to guide targeted therapy, poor understanding of the urinary microbiome’s role in infection susceptibility, and insufficient research into immunomodulatory interventions that could address the underlying mechanisms of recurrence and resistance development.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What gaps exist in current therapies for uncomplicated UTIs, particularly regarding the management of recurrence rates and the development of antibiotic resistance
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
ATTR-CM Incidence, Prevalence Rose Sharply in the US
2
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
3
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
4
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
5






